Assembly Biosciences, Inc. entered into a collaboration agreement with Gilead Sciences, Inc. for the licensing of certain programs and potential future pipeline programs, with Gilead making an upfront cash payment of $85 million and an equity investment of $15 million in Assembly Biosciences.